Evidence map›Paper›PMID 22675538›Full record

ArticlePloS one2012

Genome haploidisation with chromosome 7 retention in oncocytic follicular thyroid carcinoma.

Willem E Corver, Dina Ruano, Karin Weijers, Wietske C E den Hartog, Merlijn P van Nieuwenhuizen, Noel de Miranda, Ronald van Eijk, Anneke Middeldorp, Ekaterina S Jordanova, Jan Oosting and 5 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 86 citations in OpenAlex.

  1. Molecular Diagnostics and [Thyroid : official journal of the American Thyroid Association · 2024
    Trial
  2. Genomics and Multi-Omics to Guide Clinical Management in Thyroid Cancer.International journal of molecular sciences · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Diagnosing the silent: the molecular landscape of non-functional parathyroid carcinoma.Virchows Archiv : an international journal of pathology · 2025
    Review
  9. Review
  10. Article
  11. Case Report:Frontiers in oncology · 2025
    Article
  12. Article
  13. Article
  14. Review
  15. Progress in Thyroid Cancer Genomics: A 40-Year Journey.Thyroid : official journal of the American Thyroid Association · 2023
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Willem E CorverDepartment of Pathology, Leiden University Medical Center, Leiden, The Netherlands. w.e.corver@lumc.nl
Dina Ruano
Karin Weijers
Wietske C E den Hartog
Merlijn P van Nieuwenhuizen
Noel de Miranda
Ronald van Eijk
Anneke Middeldorp
Ekaterina S Jordanova
Jan Oosting
Ellen Kapiteijn
Guido Hovens
Jan Smit
Tom van Wezel
Hans Morreau
Leiden University Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecurrent non-medullary thyroid carcinoma (NMTC) is a rare disease. We initially characterized 27 recurrent NMTC: 13 papillary thyroid cancers (PTC), 10 oncocytic follicular carcinomas (FTC-OV), and 4 non-oncocytic follicular carcinomas (FTC). A validation cohort composed of benign and malignant (both recurrent and non-recurrent) thyroid tumours was subsequently analysed (n = 20).

methodsData from genome-wide SNP arrays and flow cytometry were combined to determine the chromosomal dosage (allelic state) in these tumours, including mutation analysis of components of PIK3CA/AKT and MAPK pathways.

resultsAll FTC-OVs showed a very distinct pattern of genomic alterations. Ten out of 10 FTC-OV cases showed near-haploidisation with or without subsequent genome endoreduplication. Near-haploidisation was seen in 5/10 as extensive chromosome-wide monosomy (allelic state [A]) with near-haploid DNA indices and retention of especially chromosome 7 (seen as a heterozygous allelic state [AB]). In the remaining 5/10 chromosomal allelic states AA with near diploid DNA indices were seen with allelic state AABB of chromosome 7, suggesting endoreduplication after preceding haploidisation. The latter was supported by the presence of both near-haploid and endoreduplicated tumour fractions in some of the cases. Results were confirmed using FISH analysis. Relatively to FTC-OV limited numbers of genomic alterations were identified in other types of recurrent NMTC studied, except for chromosome 22q which showed alterations in 6 of 13 PTCs. Only two HRAS, but no mutations of EGFR or BRAF were found in FTC-OV. The validation cohort showed two additional tumours with the distinct pattern of genomic alterations (both with oncocytic features and recurrent).

conclusionsWe demonstrate that recurrent FTC-OV is frequently characterised by genome-wide DNA haploidisation, heterozygous retention of chromosome 7, and endoreduplication of a near-haploid genome. Whether normal gene dosage on especially chromosome 7 (containing EGFR, BRAF, cMET) is crucial for FTC-OV tumour survival is an important topic for future research. MICROARRAYS: Data are made available at GEO (GSE31828).

Indexed as

HaploidyAdenocarcinoma, FollicularAgedAged, 80 and overAllelesCarcinoma, NeuroendocrineChromosomes, Human, Pair 7Cohort StudiesDisease ProgressionDNA Mutational AnalysisDNA, NeoplasmFemaleFlow CytometryGene DosageGenes, NeoplasmGenome, HumanDNA, Neoplasm

Identifiers

PMID22675538
PMCPMC3365880
OpenAlexW2117666679

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.